[
    [
        {
            "time": "",
            "original_text": "继乐普医疗收购后，物产化工又出手新东港药业45%股份",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "物产化工",
                    "新东港药业",
                    "收购"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "继乐普医疗收购后，物产化工又出手新东港药业45%股份",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[看好评级] 医药生物行业2017年年报业绩前瞻：稳健增长 分化明显 重点关注意优质成长与稳健价值",
            "features": {
                "keywords": [
                    "医药生物",
                    "2017年年报",
                    "稳健增长",
                    "分化明显",
                    "优质成长",
                    "稳健价值"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[看好评级] 医药生物行业2017年年报业绩前瞻：稳健增长 分化明显 重点关注意优质成长与稳健价值",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业日报：FDA批准吉利德治疗HIV-1感染新药上市",
            "features": {
                "keywords": [
                    "医药生物",
                    "FDA",
                    "吉利德",
                    "HIV-1",
                    "新药上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业日报：FDA批准吉利德治疗HIV-1感染新药上市",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]